Research Highlights

Recent discoveries from PARCC teams

Subgroup analysis: effect of atenolol versus bisoprolol on major adverse cardiovascular events
NEJM Evidence

Atenolol or Bisoprolol after Myocardial Infarction without Recorded Heart Failure

Laurenceau T, Meli U, … Empana JP, Bacry E, Jouven X

Using French national health data on 11,558 patients treated in the Paris area after a myocardial infarction and with no sign of heart failure, the team compared the two most prescribed beta-blockers. Starting atenolol was associated with fewer major cardiovascular events at two years than bisoprolol, without a significant difference in overall mortality.

Subgroup analysis from Laurenceau et al., NEJM Evidence 2026 — © Massachusetts Medical Society.

Read the article →
Figure 1: study design and consensus clustering of heart failure patients
Nature Communications

Multimodal data-driven clustering identifies two distinct patterns of heart failure with preserved ejection fraction

Hulot JS, Hervé PY, Girerd N, … Logeart D, on behalf of the PACIFIC consortium

In the PACIFIC-Preserved cohort, combining clinical data, cardiac imaging and high-throughput plasma proteomics with machine learning split patients with HFpEF into two biologically distinct groups. The inflammatory group, marked by cardio-skeletal injury and renal dysfunction, carried a higher risk of adverse outcomes in an external validation cohort.

Fig. 1 from Hulot et al., Nat Commun 2026 — CC BY-NC-ND 4.0.

Read the article →
Figure 1: mice lacking circulating S1P have lower blood pressure
PNAS

Blood-borne sphingosine 1-phosphate maintains vascular resistance, blood pressure, and cardiac function in mice

Del Gaudio I, Bonnin P, Vessières E, … Henrion D, Camerer E

Sphingosine 1-phosphate (S1P), a lipid released by red blood cells, circulates bound to HDL or albumin. Mice lacking all circulating S1P had low blood pressure and weaker heart contraction, both corrected by transfusing S1P-producing red cells. Albumin-bound S1P increased vascular resistance through the S1PR3 and S1PR2 receptors.

Fig. 1 from Del Gaudio et al., PNAS 2026 — CC BY-NC-ND 4.0.

Read the article →

Parcc Communities

Follow us on LinkedIn

So you don't miss any of our news.

BlueSky Posts